Baize

Baize (Shanghai Baize Medical Technology) is a clinical-stage biotechnology company and a core subsidiary of the Shanghai Cell Therapy Group. The company focuses on the development of next-generation cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) treatments for solid tumors. Utilizing its proprietary Baize platform, the company aims to overcome the immunosuppressive microenvironment of solid tumors through innovative cell engineering and antibody discovery. Baize's pipeline includes candidates targeting GPC3 for liver cancer and MSLN for various solid malignancies, with several programs currently in clinical trials. The company is a key component of the broader Baize Plan, which integrates cell storage, precision medicine, and therapeutic development to improve human health and longevity.